SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Strange who wrote (1450)10/20/1998 9:37:00 PM
From: Ariella  Read Replies (1) of 1491
 
Rick, I thought the split was not 50-50 and that's why more are getting dex in the third cohort.

First two cohorts of Phase II:
dex -- 30 patients..........placebo -- 37 patients

If 20 more are added for part 3, Phase II:
dex ~ 13 patients.........placebo ~ 7 patients

Total for all three (87 patients):
dex ~ 43 patients..........placebo ~ 44 patients
-----------------------------------------------------------------------
If 30 patients are added for part 3:
dex ~ 20 patients............placebo ~ 10 patients

Total for all three (97 patients):
dex ~ 50 patients.............placebo ~ 47 patients

I just figured we needed more headcount on the dex side (and, by the way, why didn't it come out roughly 50-50 to begin with?).

-Ariella

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News